Drugs / GSK2336805
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT02018536 | Oct 2013 → Mar 2014 | — | Janssen R&D Ireland | Completed | No outcome recorded |
| Phase 1 | NCT01827657 | May 2013 → Mar 2014 | hepatitis C virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01458054 | Sep → Nov 2011 | hepatitis C virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01424540 | Sep → Oct 2011 | hepatitis C virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01277692 | Nov 2010 → May 2011 | chronic hepatitis C virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT01724086 | Oct 2012 → Sep 2014 | chronic hepatitis C virus infection | Janssen R&D Ireland | Completed | No outcome recorded |
| Phase 2 | NCT01648140 | Aug 2012 → Jul 2014 | chronic hepatitis C virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01439373 | Jul → Dec 2011 | chronic hepatitis C virus infection | GlaxoSmithKline | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2012-11-01 | Vertex Pharmaceuticals Incorporated | Vertex Enters Agreement with GlaxoSmithKline for Phase 2 All-Oral Study of VX-135 and GSK2336805 for the Treatment of Hepatitis C vrtx.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2336805 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01277692 ↗ |
| Action | Inhibit | “GSK2336805 is a hepatitis C virus NS5A inhibitor in clinical development for the treatment of chronic hepatitis C virus infection.” PMID 23856771 ↗ Jul 2013 |
| Route | Oral | “Oral Administration of GSK2336805” NCT01648140 ↗ |